Authors
Loading...
Observational analysis revealed that TET2 mutations enhance type I interferon production in HSPCs, suggesting a potential therapeutic target via TRIM4 silencing.
Jaud et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: